Results 61 to 70 of about 24,877 (187)
Clinical manifestations of dual‐gene variants in retinitis pigmentosa
Acta Ophthalmologica, EarlyView.Abstract Purpose Retinitis pigmentosa (RP) is an inherited retinal disease (IRD), whereby each affected individual typically harbours pathogenic variants in a single causative gene, yet the disorder exhibits marked genetic heterogeneity, with more than 100 genes reported to underlie RP.
Lasse Wolfram +11 more
wiley +1 more source
Retinal dystrophies simulating geographic atrophy: A diagnostic challenge
Acta Ophthalmologica, EarlyView.Abstract Geographic atrophy (GA) is the chronic loss of retinal pigment epithelium, photoreceptors and choriocapillaris, marking the dry late stage of age‐related macular degeneration (AMD). GA prevalence is expected to rise in the upcoming decades. Advanced GA leads to central scotomas, reducing visual acuity and quality of life, potentially resulting
Johanna M. Colijn +3 more
wiley +1 more source
Clinical Genetics, EarlyView.Opticus atrophy—Genetic testing with WES/WGS in 62 patients with optic atrophy provided a genetic diagnosis in 21 patients (33.9%). 42.9% of these involved non‐OPA1 genes, including WFS1, ACO2, NR2F1, UCHL1, CACNA1F, and COQ2, where the genetic diagnosis prompted additional clinical evaluation, surveillance, or therapeutic intervention.
Katrine M. Johannesen +9 more
wiley +1 more source
Effect of Adding Losartan to Bevacizumab for Treating Diabetic Macular Edema
Journal of Ophthalmology, 2020 Introduction. Diabetic retinopathy is the most common cause of visual loss and blindness in the age group of 20 to 64 years. This study aimed to evaluate the efficacy of oral Losartan adjuvant therapy in combination with intravitreal injection of ...
Fariba Ghassemi +4 more
doaj +1 more source
Diabetic Medicine, EarlyView.Abstract Aims Diabetic macular edema (DME) is a leading cause of vision loss among individuals with diabetes. While anti‐VEGF therapy is a widely used and effective treatment, limited research has explored participants' lived experiences throughout the treatment process.
J. K. Leksell +3 more
wiley +1 more source
Indian Journal of Ophthalmology, 2006 Diabetic retinopathy is fast emerging as a leading cause of newly diagnosed legal blindness amongst the working population. Macular edema, as it is commoner, accounts for more vision impairment than neovascular proliferation in diabetic patients.
Vedantham Vasumathy, Kim Ramasamy
doaj
Diabetic macular edema: it is more than just VEGF [version 1; referees: 2 approved]
F1000Research, 2016 Diabetic macular edema is a serious visual complication of diabetic retinopathy. This article reviews the history of previous and current therapies, including laser therapy, anti-vascular endothelial growth factor agents, and corticosteroids, that have ...
Michael A. Singer +4 more
doaj +1 more source
Topical Interferon Alpha 2b in the Treatment of Refractory Diabetic Macular Edema
Journal of Ophthalmic & Vision Research, 2020 Purpose: To report the efficacy of topical interferon alpha 2b in the treatment of refractory diabetic macular edema. Methods: In this retrospective interventional case series, five eyes of three individuals with diabetic macular edema resistant to
Arash Maleki +2 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To assess whether glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are associated with a lower incidence of age‐related ocular diseases in non‐diabetic older adults with overweight or obesity. Materials and Methods We conducted a retrospective, propensity score–matched cohort study using the TriNetX global research network.
Kuo‐En Chen +3 more
wiley +1 more source
Caspian Journal of Internal Medicine, 2015 Background: Diabetes is a common metabolic disorder leading to the development of many complications, among which diabetic retinopathy and macular edema are the most significant. These complications can contribute to blindness if not diagnosed or treated
Seyed Ahmad Rasoulinejad +1 more
doaj